Sector
PharmaceuticalsOpen
₹1.9Prev. Close
₹2Turnover(Lac.)
₹0.99Day's High
₹2.1Day's Low
₹1.952 Week's High
₹052 Week's Low
₹0Book Value
₹-1.53Face Value
₹5Mkt Cap (₹ Cr.)
7.16P/E
0EPS
0Divi. Yield
0
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 17.05 | 17.05 | 17.05 | 17.05 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -22.28 | -22.13 | -19.1 | 4.57 |
Net Worth | -5.23 | -5.08 | -2.05 | 21.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 106.66 | 139.55 | 109.14 | 91.04 |
yoy growth (%) | -23.56 | 27.86 | 19.87 | 17.33 |
Raw materials | -116.55 | -108.63 | -81.75 | -72.26 |
As % of sales | 109.26 | 77.84 | 74.9 | 79.37 |
Employee costs | -7.33 | -4.06 | -3.67 | -3.45 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -47.82 | 5.64 | 0.87 | -8.83 |
Depreciation | -4.7 | -4.03 | -3.87 | -2.21 |
Tax paid | 0 | -1.17 | -0.73 | 1.7 |
Working capital | -37.04 | -0.89 | 1.39 | -20.04 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -23.56 | 27.86 | 19.87 | 17.33 |
Op profit growth | -383.21 | 35.97 | -635.59 | -114.31 |
EBIT growth | -423.16 | 125.44 | -244.96 | -135.63 |
Net profit growth | -2,284.46 | 1,472.98 | -102.22 | -178.94 |
| Particulars (Rupees in Crores.) | Mar-2015 | Mar-2014 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Gross Sales | 72.23 | 68.41 | 44.7 | 36.22 |
Excise Duty | 7.19 | 6.73 | 0 | 0 |
Net Sales | 65.04 | 61.68 | 44.7 | 36.22 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.2 | 0.1 | 0.17 | 0.07 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,786.05 | 155.44 | 4,28,533.22 | 863.29 | 0.76 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,766.25 | 83.33 | 1,53,075.82 | 518 | 0.52 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,470.05 | 28.04 | 1,18,723.3 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Dr Reddys Laboratories Ltd DRREDDY | 1,354.2 | 23.49 | 1,12,997.69 | 1,882.1 | 0.59 | 6,678.8 | 322.47 |
Mankind Pharma Ltd MANKIND | 2,738.25 | 56.37 | 1,12,971.13 | 634.43 | 0 | 2,529.74 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mukesh D Naik
Independent Director
Vinod Laxman Parab
Non-Exec. & Independent Dir.
Nitin Desai
Company Secretary
Nancy Napoleon
Non-Exec. & Independent Dir.
Leena Chitalia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Nutraplus India Ltd
Summary
Nutraplus Products (India) Limited was originally incorporated as a private limited company on 6 Feb.90. It was subsequently converted into a public limited company with effect from 13 Jun.92. The company implemented a project for the manufacture of veterinary bulk drugs namely dimentridazole (DMZ) and dinitolmide (DOT) at Tarapur, Maharashtra. Initially, the company set up manufacturing facilities for the manufacture of methyl nitro imidazole, an intermediate of DMZ, with an installed capacity of 240 tpa, at a cost of Rs 123.66 lac, for which was sanctioned a term loan of Rs 60 lac from the Maharashtra State Financial Corporation (MSFC).The company has set-up new product Roxarsone from Jan96 and also set up production of Dinitolmide. During 2001-02 the company set up a production of newly developed Bulk Drugs Metformin HCL. It is also planning to foray in the manufacture of life saving drugs.
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
